Trying to Conceive on a GLP-1: Fertility, Washout Timing, and the Honest Evidence

A drug that can help you conceive — and that you cannot take while conceiving

There is a paradox at the center of GLP-1s and fertility, and it is worth naming plainly before anything else. The same medication that can restore an ovulation you have not seen in months is also a medication you are meant to stop before you try to get pregnant. Both halves are true at once. Understanding why is the difference between an unplanned scare and a planned, intentional path to a pregnancy.

The "Ozempic baby" stories that circulated were not a myth and not magic. They were biology doing exactly what the trials predict: in women whose cycles had gone quiet under the weight of obesity or PCOS, losing weight and easing insulin resistance let ovulation return — sometimes before anyone updated their assumptions about contraception. If you have spent years believing you could not easily conceive, that is a genuinely destabilizing thing to have change silently.

The fertility upside is real, and it is mostly mechanical

The evidence for a fertility benefit is best read as a benefit of what the drug does — weight and insulin — rather than a direct fertility drug effect. A 2026 narrative review of reproductive outcomes concluded that GLP-1 receptor agonists may improve ovulatory function and menstrual regularity, particularly in women with obesity or polycystic ovary syndrome, plausibly increasing the likelihood of conception¹. The most concrete trial evidence is narrow but pointed: obese women with PCOS who had responded poorly to a first IVF cycle achieved higher pregnancy rates after a course of liraglutide with metformin². A dedicated 2026 fertility review reaches the same careful conclusion — a plausible pro-fertility effect, driven largely by metabolic improvement, on a still-thin evidence base³.

If your infertility is tied to weight or PCOS, in other words, a GLP-1 may be part of the preparation for pregnancy. It is the runway, not the takeoff. Our deeper look at GLP-1s and PCOS walks through how much of this rides on the metabolic engine.

Why you have to stop — and the washout arithmetic

The reason for stopping is not squeamishness; it is that human pregnancy-safety data are genuinely limited, and what data exist come from small, uncontrolled reports. A 2026 case series of pregnancies exposed to GLP-1s illustrates the state of the evidence: individual outcomes, not a reassuring population-level dataset⁴. Reviews consistently describe the human pregnancy data as insufficient to call the drugs safe, even where no strong teratogenic signal has yet emerged¹. When the answer is "we don't have enough data," the responsible default in a planned pregnancy is to not expose the pregnancy at all.

That is why the FDA label is specific about timing. The Wegovy (semaglutide) label instructs women to discontinue the drug at least two months before a planned pregnancy, precisely because of its long washout — the medication lingers in the body for weeks after the last dose⁵. This is the single most important operational fact in this piece: stopping is not a same-week decision. It is a two-month-ahead decision, which means you plan the stop on the same calendar where you plan the try. Bring that calendar to the conversation you have with your OB first.

The contraception catch that traps people going the other way

The mirror-image risk is for women who are not trying to conceive. Because a GLP-1 can quietly restore ovulation, contraception matters more on the drug than it may have before it — not less. And with tirzepatide (Zepbound, Mounjaro) there is a second, distinct problem: its label carries an explicit warning that oral hormonal contraceptives may become less effective, and advises switching to a non-oral method or adding a barrier method around starting the drug and around each dose increase⁶. So the very medication that can reopen fertility can, if you take the tirzepatide family, also blunt the pill you were relying on. That is a two-sided trap, and it is exactly why we devote a whole piece to GLP-1s and birth control.

Building the actual timeline

Put the pieces together and a real trying-to-conceive plan on a GLP-1 looks like this — and every date belongs to you and your clinician, not to a rule of thumb:

1. 1.While on the drug: treat restored ovulation as real. If you are not ready to conceive, use reliable contraception, and a non-oral or barrier method if you are on tirzepatide⁶.
2. 2.When you decide to try: plan the stop first. Under the semaglutide label that is at least two months before you begin trying, to let the drug clear⁵. Your clinician may fold in folate and a general preconception check here.
3. 3.After stopping: expect appetite and some weight to return as the medication leaves — that is the drug wearing off, not a personal failure. Our guide to coming off a GLP-1 and the rebound question covers that stretch honestly.
4. 4.After the baby: if you plan to breastfeed, the drug stays off the table; restarting is a later, separate conversation.

The honest bottom line

A GLP-1 can be part of getting ready to conceive — especially if weight or PCOS is in the picture — and must be out of your system before you actually do. The women who navigate this well are the ones who plan the stop as deliberately as the start, with a clinician who can time the washout, manage the contraception, and switch molecules if needed. That kind of oversight is what our Editors' Rating methodology rewards, and why a clinician-led program like CoreAge Rx sits at the top of our board of GLP-1 programs for moms — a good program plans your exit as carefully as your entrance. This essay is educational only and is not medical advice; every date here is one to set with your own clinician.